On Sun, 30 May 1999 15:19:52 -0300, "Julia Muller Dias"
<ironwood at zaz.com.br> wrote:
>Dear Sirs
>>We need informations about glycine, like co-agonist in the treatment of
>schizophrenia.
>>Best regards.
>Vladimir D. Dias
I don't have the exact references about glycine's effectiveness in
augmenting normal antipsychotic therapy, but I have some names, so
hopefully that wil help you. As far as I recall so far there has been
no current study conclusively showing glycine having antipsychotic
effects on its own.
Waziri et al (ref?) showed in a clinical study, that high doses of
glycine (5-25 g/day) administered ot schizophrenics produced
improvement in 4 out of 11 patients. However another study by Potkin
et al (ref?) was unable to replicate the finding and only reported
modest improvements in 1 out of 8 schizophrenics.A separate study
using low dose milacemide (a proglycine drug) produced no change in
behaviour (Rosse et al, 1991)
However, combining the neuroleptic treatment with glycine was much
more efficacious. Nussenzweig et al and Potkin et al conducted
double-blind studies showing combined treatment produced overall
improvement in a subgroup of schizophrenics. It is proposed by Zukin
et al that this therapeutic effect is confined to the negative
symptoms of schizophrenia based on the Wisconsin Card Sort Task.
Additionally, this probably isn't helpful, but a monoclonal antibody
(B6B21) and the amino acid, d-cylcoserine binds to the glycine site as
well and enhances hippocampus-dependent learning (Thompson et al,
1992). I don't know if either of these have been tested in models for
schizophrenia.
Hopfully some of these references are of help
Nussenzweig et al (1992) Presentation at the 145th Annual Meeting of
the American Psychiatric Association, Washington DC.
Rosse et al (1991) Clinical neuropharmacology, vol 14, pg 268
Porkin et al (1992) HY Meltzer's "Novel antipsychotic drugs" by New
York Press, pg 179-188
Thompson et al (1992) Nature, vol 359, pg 638
Warizi et al (?)
Zukin et al (?)